MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn mice
Nacho Aguilo, Santiago Uranga, Dessislava Marinova, Marta Monzon, Juan Badiola, Carlos Martin, Nacho Aguilo, Santiago Uranga, Dessislava Marinova, Marta Monzon, Juan Badiola, Carlos Martin
Abstract
Development of novel more efficient preventive vaccines against tuberculosis (TB) is crucial to achieve TB eradication by 2050, one of the Millennium Development Goals (MDG) for the current century. MTBVAC is the first and only live attenuated vaccine based on a human isolate of Mycobacterium tuberculosis developed as BCG-replacement strategy in newborns that has entered first-in-human adult clinical trials. In this work, we characterize the safety, immunogenicity and protective efficacy of MTBVAC in a model of newborn C57/BL6 mice. Our data clearly indicate that MTBVAC is safe for newborn mice, and does not affect animal growth or organ development. In addition, MTBVAC-vaccinated mice at birth showed enhanced immunogenicity and better protection against M. tuberculosis challenge in comparison with BCG.
Keywords: MTBVAC; Neonates; Newborn mice; Tuberculosis vaccine.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.
Figures
References
- Marinova D., Gonzalo-Asensio J., Aguilo N., Martin C. Recent developments in tuberculosis vaccines. Expert Rev Vaccines. 2013;12(12):1431–1448.
- Mangtani P., Abubakar I., Ariti C., Beynon R., Pimpin L., Fine P.E., Rodrigues L.C., Smith P.G., Lipman M., Whiting P.F., Sterne J.A. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis. 2014;58(4):470–480.
- Pym A.S., Brodin P., Brosch R., Huerre M., Cole S.T. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol. 2002;46(3):709–717.
- Brosch R., Gordon S.V., Garnier T., Eiglmeier K., Frigui W., Valenti P., Dos Santos S., Duthoy S., Lacroix C., Garcia-Pelayo C., Inwald J.K., Golby P., Garcia J.N., Hewinson R.G., Behr M.A., Quail M.A., Churcher C., Barrell B.G., Parkhill J., Cole S.T. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci U S A. 2007;104(13):5596–5601.
- Copin R., Coscolla M., Efstathiadis E., Gagneux S., Ernst J.D. Impact of in vitro evolution on antigenic diversity of Mycobacterium bovis bacillus Calmette–Guerin (BCG) Vaccine. 2014;32(45):5998–6004.
- Brites D., Gagneux S. Co-evolution of Mycobacterium tuberculosis and homo sapiens. Immunol Rev. 2015;264(1):6–24.
- Arbues A., Aguilo J.I., Gonzalo-Asensio J., Marinova D., Uranga S., Puentes E., Fernandez C., Parra A., Cardona P.J., Vilaplana C., Ausina V., Williams A., Clark S., Malaga W., Guilhot C., Gicquel B., Martin C. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine. 2013;31(42):4867–4873.
- Gonzalo-Asensio J., Mostowy S., Harders-Westerveen J., Huygen K., Hernandez-Pando R., Thole J., Behr M., Gicquel B., Martin C. PhoP: a missing piece in the intricate puzzle of Mycobacterium tuberculosis virulence. PLoS One. 2008;3(10):e3496.
- Camacho L.R., Ensergueix D., Perez E., Gicquel B., Guilhot C. Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis. Mol Microbiol. 1999;34(2):257–267.
- Spertini F., Audran R., Chakour R., Karoui O., Steiner-Monard V., Thierry A.-C., Mayor C.E., Rettby N., Jaton K., Vallotton L., Lazor C., Doce J., Puentes E., Marinova D., Aguilo N., Martin C. Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial. Lancet Respir Med. 2015;3(12):953–962.
- Guerrero G.G., Debrie A.S., Locht C. Boosting with mycobacterial heparin-binding haemagglutinin enhances protection of Mycobacterium bovis BCG-vaccinated newborn mice against M. tuberculosis. Vaccine. 2010;28(27):4340–4347.
- Tameris M.D., Hatherill M., Landry B.S., Scriba T.J., Snowden M.A., Lockhart S., Shea J.E., McClain J.B., Hussey G.D., Hanekom W.A., Mahomed H., McShane H. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013;381(9871):1021–1028.
- Beverley P. TB vaccine failure was predictable. Nature. 2013;503(7477):469.
- Kashangura R., Sena E.S., Young T., Garner P. Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review. Int J Epidemiol. 2015 Sep 8 pii: dyv142.
- Martin C., Williams A., Hernandez-Pando R., Cardona P.J., Gormley E., Bordat Y., Soto C.Y., Clark S.O., Hatch G.J., Aguilar D., Ausina V., Gicquel B. The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine. 2006;24(17):3408–3419.
- Solans L., Uranga S., Aguilo N., Arnal C., Gomez A.B., Monzon M., Badiola J.J., Gicquel B., Martin C. Hyper-attenuated MTBVAC erp mutant protects against tuberculosis in mice. Vaccine. 2014;32(40):5192–5197.
- Horwitz M.A., Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect Immun. 2003;71(4):1672–1679.
Source: PubMed